Larimar Therapeutics, Inc. (LRMR) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Bala Cynwyd, PA, 美国. 现任CEO为 Carole S. Ben-Maimon.
LRMR 拥有 IPO日期为 2014-06-19, 65 名全职员工, 在 NASDAQ Global Market, 市值为 $416.77M.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
